ATE535241T1 - Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie - Google Patents

Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie

Info

Publication number: ATE535241T1
Authority: AT; Austria
Prior art keywords: azaindolyl; indolyl; leukemia; treatment; phenyl
Prior art date: 2007-12-05

Application number

AT08857282T

Other languages

English (en)

Inventor

Gerd Dannhardt

Thomas Fischer

Florian Heidel

Jan-Peter Kramb

Stanislav Plutizki

Original Assignee

Univ Mainz Johannes Gutenberg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-05

Filing date

2008-12-04

Publication date

2011-12-15

2008-12-04 Application filed by Univ Mainz Johannes Gutenberg filed Critical Univ Mainz Johannes Gutenberg

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE535241T1 publication Critical patent/ATE535241T1/de

Links

208000032839 leukemia Diseases 0.000 title abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000005842 heteroatom Chemical group 0.000 abstract 2
229910052757 nitrogen Inorganic materials 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
125000006413 ring segment Chemical group 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
229910052717 sulfur Inorganic materials 0.000 abstract 2
125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000001041 indolyl group Chemical group 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Hematology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

AT08857282T 2007-12-05 2008-12-04 Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie ATE535241T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07023588		2007-12-05
PCT/EP2008/066776 WO2009071620A1 (en)	2007-12-05	2008-12-04	Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management

Publications (1)

Publication Number	Publication Date
ATE535241T1 true ATE535241T1 (de)	2011-12-15

Family

ID=40328303

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08857282T ATE535241T1 (de)	2007-12-05	2008-12-04	Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie

Country Status (7)

Country	Link
US (1)	US8841319B2 (de)
EP (1)	EP2217231B1 (de)
JP (1)	JP5576290B2 (de)
AT (1)	ATE535241T1 (de)
AU (1)	AU2008333215B2 (de)
CA (1)	CA2707554C (de)
WO (1)	WO2009071620A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5699129B2 (ja)	2009-04-14	2015-04-08	イーライリリーアンドカンパニー	造血器新生物および白血病の治療のためのベンゾジアゼピン誘導体
EP2338486A1 (de)	2009-12-18	2011-06-29	Johannes Gutenberg-Universität Mainz	3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Derivaten zurVerwendung in der Behandlung von Colon und Magen Adenocarzinoma
EP2343291A1 (de)	2009-12-18	2011-07-13	Johannes Gutenberg-Universität Mainz	3-(Indolyl)- oder 3-(Azaindolyl)-4-Arylmaleimid-Verbindungen und ihre Verwendung bei der Behandlung von Tumoren
EP2474541A1 (de) *	2010-12-23	2012-07-11	Johannes- Gutenberg-Universität Mainz	Konjugierte 3-(Indolyl)- und 3-(Azaindolyl)-4-arylmaleinimid-Verbindungen und deren Verwendung bei der Behandlung von Tumoren
EA025186B1 (ru)	2012-06-29	2016-11-30	Пфайзер Инк.	НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
US9724331B2 (en) *	2012-12-10	2017-08-08	Centogene Ag	Use of maleimide derivatives for preventing and treating leukemia
US9993463B2 (en) *	2012-12-10	2018-06-12	Centogene Ag	Use of maleimide derivatives for preventing and treating cancer
EP3083618B1 (de)	2013-12-17	2018-02-21	Pfizer Inc	Neuartige 3,4-disubstituierte-1h-pyrrolo[2,3-b]pyridine und 4,5-disubstituierte 7h-pyrrolo[2,3-c]pyridazine als lrrk2-hemmer
RU2722149C1 (ru)	2015-09-14	2020-05-27	Пфайзер Инк.	Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
EP3187495A1 (de)	2015-12-30	2017-07-05	Johannes Gutenberg-Universität Mainz	3-(5-fluorindolyl)-4-arylmaleimid-verbindungen und deren verwendung bei der tumorbehandlung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1253449C (zh) *	2000-11-07	2006-04-26	诺瓦提斯公司	作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
CA2485527A1 (en) *	2002-05-08	2003-11-20	Janssen Pharmaceutica N.V.	Substituted pyrroline kinase inhibitors
ES2312785T3 (es) *	2002-06-05	2009-03-01	Janssen Pharmaceutica Nv	Pirrolinas sustituidas utiles como inhibidores de quinasa.
JP2006521386A (ja)	2003-03-27	2006-09-21	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	キナーゼ阻害剤である置換ピロリン
JP5289769B2 (ja) *	2004-12-08	2013-09-11	ヨハネス、グーテンベルク−ウニフェルジテート、マインツ	３−（インドリル）−４−アリールマレイミド誘導体および脈管形成阻害剤としてのそれらの使用

2008
- 2008-12-04 EP EP08857282A patent/EP2217231B1/de not_active Not-in-force
- 2008-12-04 AT AT08857282T patent/ATE535241T1/de active
- 2008-12-04 WO PCT/EP2008/066776 patent/WO2009071620A1/en not_active Ceased
- 2008-12-04 US US12/746,630 patent/US8841319B2/en not_active Expired - Fee Related
- 2008-12-04 CA CA2707554A patent/CA2707554C/en not_active Expired - Fee Related
- 2008-12-04 AU AU2008333215A patent/AU2008333215B2/en not_active Ceased
- 2008-12-04 JP JP2010536454A patent/JP5576290B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2707554A1 (en)	2009-06-11
US8841319B2 (en)	2014-09-23
EP2217231B1 (de)	2011-11-30
EP2217231A1 (de)	2010-08-18
WO2009071620A1 (en)	2009-06-11
US20110028415A1 (en)	2011-02-03
JP2011506288A (ja)	2011-03-03
CA2707554C (en)	2015-06-30
JP5576290B2 (ja)	2014-08-20
AU2008333215A1 (en)	2009-06-11
AU2008333215B2 (en)	2013-06-13

Similar Documents

Publication	Publication Date	Title
GEAP202215535A (en)	2022-04-11	Compounds
MX2021009763A (es)	2021-09-08	Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
EA200970461A1 (ru)	2009-12-30	ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201290260A1 (ru)	2013-12-30	Бензимидазол-имидазольные производные
HUP0303637A2 (hu)	2004-03-01	Nitrogéntartalmú spirotriciklusos-származékok, eljárás előállításukra, valamint ezeket tartalmazó foszfodiészteráz-7-inhibitorként alkalmazható gyógyszerkészítmények
NO20061406L (no)	2006-08-25	Organiske forbindelser
EA200501617A1 (ru)	2006-04-28	Новые гетероциклические соединения, применяемые для лечения нарушений аллергической или воспалительной природы: способы синтеза и содержащие их фармацевтические составы
CY1113099T1 (el)	2016-04-13	Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
EA200702497A1 (ru)	2008-06-30	Замещенные арилпиразолы для применения против паразитов
CY1109821T1 (el)	2014-09-10	Ενωσεις πιπεραζινης με ζιζανιοκτονα δραση
TW200833675A (en)	2008-08-16	Nicotinamide derivatives
EA201200875A1 (ru)	2013-01-30	Ингибиторы сфингозинкиназы
NO20083598L (no)	2008-10-20	Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase
DE602004011199D1 (de)	2008-02-21	5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
CY1106881T1 (el)	2012-09-26	(3-οξο-3,4-διυδρο-κινοξαλιν-2-υλο-αμινο) - βενζαμιδικα παραγωγα και σχετικες ενωσεις ως αναστολεις της φωσφορυλασης γλυκογονου για την αντιμετωπιση του διαβητη και της παχυσαρκιας.
NO20083207L (no)	2008-09-17	Inhibitorer av IAP
NO20075384L (no)	2007-11-30	Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer.
CY1114767T1 (el)	2016-12-14	Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων
NO20092286L (no)	2009-08-13	Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
AR070797A1 (es)	2010-05-05	Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes
TW200612936A (en)	2006-05-01	Indole derivatives
CY1114865T1 (el)	2016-12-14	Νεοι αναστολεις seh και η χρηση toyς
EA202192900A1 (ru)	2022-03-18	Модуляторы пути интегрированной реакции на стресс
AR070635A1 (es)	2010-04-21	DERIVADOS DE PIRIDOPIRAZINONA QUE ESTIMULAN LA SECRECIoN DE INSULINA, MÉTODOS PARA OBTENERLOS, SU USO EN EL TRATAMIENTO DE LA DIABETES Y COMPOSICIONES FARMACEUTICAS.
CY1123488T1 (el)	2022-03-24	Πεντακυκλοθειενυλο και ινδανυλο παραγωγα ουριας ως παραγοντες διανοιξης διαυλου καλιου